Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119223 | 0.89 | EPHX2 (0.60) | EPHX2KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL29401765 | 0.89 | EPHX2 (0.60) | EPHX2KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL29913938 | 0.89 | EPHX2 (0.60) | EPHX2KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL6346117 | 0.86 | EPHX2 (0.52) | EPHX2KMT2ACASP3 | |
| SCHEMBL3209124 | 0.84 | EPHX2 (0.55) | EPHX2KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL3212368 | 0.83 | EPHX2 (0.57) | EPHX2KMT2ACASP3KDM4E | |
| SCHEMBL3221146 | 0.83 | EPHX2 (0.54) | EPHX2KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL3199951 | 0.83 | EPHX2 (0.57) | EPHX2KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL28811897 | 0.82 | EPHX2 (0.55) | EPHX2KMT2AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL29342668 | 0.81 | EPHX2 (0.57) | EPHX2KMT2ANPC1RAB9ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682123-B2 | Methods of treating metabolic disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| CN-103154018-B | For passing through the antibody of affinity chromatography and the part of Fc-fusion protein purification | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-04-27 | — | — | CN | disclosed |
| US-20150190466-A1 | METHODS OF TREATING METABOLIC DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-09 | — | — | US | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| US-20130160150-A1 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE LISCH-LIKE PROTEIN OR C1ORF32 PROTEIN ACTIVITY AND METHODS OF USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2601208-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | Graffinity Pharmaceuticals GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| CN-103154018-A | Ligands for antibody and Fc-fusion protein purification by affinity chromatography | GRAFFINITY PHARMACEUTICALS GMBH | 2013-06-12 | — | — | CN | disclosed |
| US-8460880-B2 | Compositions, splice variants and methods relating to ovarian specific genes and proteins | DIADEXUS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| WO-2002039431-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038810-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002036616-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036807-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036808-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020048763-A1 | Human genome-derived single exon nucleic acid probes useful for gene expression analysis | AMERSHAM PLC (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020048800-A1 | Myosin-like gene expressed in human heart and muscle | GE HEALTHCARE LIMITED (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002026818-A2 | HUMAN NEDD-1 | AEOMICA, INT. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002024750-A2 | HUMAN KIDNEY TUMOR OVEREXPRESSED MEMBRANE PROTEIN 1 | AEOMICA, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001092524-A2 | MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE | AEOMICA, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCGR3B | EPHX2 2225/4885KMT2A 2553/4885NPC1 4079/4885 |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCER2 | EPHX2 1781/4885KMT2A 1127/4885NPC1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.